NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter ACCESSWIRE First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed the acquisition of Trapelo Health in April FORT MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the ' Company' ), a leading provider of cancer-focused genetics testing services, today announced its first-quarter results for the period ended March 31, 2021. Mark W. Mallon, the Com...